Uncarboxylated osteocalcin induces antitumor immunity against mouse melanoma cell growth

Yoshikazu Hayashi, Tomoyo Kawakubo-Yasukochi, Akiko Mizokami, Mai Hazekawa, Tomiko Yakura, Munekazu Naito, Hiroshi Takeuchi, Seiji Nakamura, Masato Hirata

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Because of the poor response to chemotherapy and radiation therapy, new treatment approaches by immune-based therapy involving activated T cells are required for melanoma. We previously reported that the uncarboxylated form of osteocalcin (GluOC), derived from osteoblasts, potentially suppresses human prostate cancer cell proliferation by direct suppression of cell growth. However, the mechanisms in vivo have not been elucidated. In this study, we found that GluOC suppressed tumor growth of B16 mouse melanoma transplants in C57Bl/6N wild-type mice. Our data demonstrated that GluOC suppressed cell growth by downregulating phosphorylation levels of receptor tyrosine kinases and inducing apoptosis in vitro. Additionally, stimulation of primary mouse splenocytes with concanavalin A, a polyclonal T-cell mitogen, in the presence of GluOC increased T cell proliferation and their interferon-γ production. Taken together, we demonstrate that GluOC exerts multiple antitumor effects not only in vitro, but also in vivo through cellular immunostimulatory effects against B16 mouse melanoma cells.

Original languageEnglish
Pages (from-to)2478-2486
Number of pages9
JournalJournal of Cancer
Volume8
Issue number13
DOIs
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Uncarboxylated osteocalcin induces antitumor immunity against mouse melanoma cell growth'. Together they form a unique fingerprint.

  • Cite this